Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Contact Us for the Latest Status
-
PAXIS: A randomized, double-blind, placebo-controlled, dose-finding phase 2 study (Part 1)
followed by an open-label period (Part 2) to assess the efficacy and safety of pacritinib in patients with
VEXAS syndrome
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this stduy is to evaluate the efficacy of two dose levels of pacritinib compared to placebo during the double-blind treatment period in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.
.